Form 4: LeMaitre Vascular CEO George W. LeMaitre Reports Acquisition of Dividend Equivalent Rights
SEC Form 4 Filing
George W. LeMaitre, Chairman and CEO of LeMaitre Vascular, reports the acquisition of dividend equivalent rights related to restricted stock unit awards.
Summary
- On March 28, 2024, George W. LeMaitre, Chairman and CEO of LeMaitre Vascular, acquired dividend equivalent rights.
- These rights are associated with restricted stock unit (RSU) and Performance Share Unit (PSU) awards previously granted to LeMaitre.
- The dividend equivalent rights vest proportionately with the underlying RSU and PSU awards.
- Each dividend equivalent right represents the economic equivalent of one share of LeMaitre Vascular's common stock.
- A total of 47.7884 dividend equivalent rights were acquired across six different grants dating from 2019 to 2023.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding executive compensation. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It reflects ongoing equity-based compensation practices.
Comparison to Industry Standards
- Equity compensation, including restricted stock units and performance share units, is a common practice among publicly traded companies, particularly in the medical device industry.
- Companies like Medtronic, Boston Scientific, and Abbott also utilize similar equity-based compensation plans to incentivize and retain key executives.
- The vesting schedules and terms of these awards are generally aligned with industry standards to ensure long-term alignment with shareholder interests.
Stakeholder Impact
- The acquisition of dividend equivalent rights has a minor impact on shareholders, as it is related to executive compensation and aligns management's interests with the company's performance.
- Employees may view this as a standard part of the executive compensation package.
Key Dates
| Date | Description |
|---|---|
| 12/20/2019 | Date of restricted stock unit award grant associated with dividend equivalent rights. |
| 12/02/2020 | Date of restricted stock unit award grant associated with dividend equivalent rights. |
| 12/11/2021 | Date of restricted stock unit award grant associated with dividend equivalent rights. |
| 12/12/2022 | Date of restricted stock unit and Performance Share Unit award grants associated with dividend equivalent rights. |
| 12/08/2023 | Date of restricted stock unit award grant associated with dividend equivalent rights. |
| 03/28/2024 | Date of transaction: Acquisition of dividend equivalent rights. |
| 04/01/2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.